Aberrations in the iron regulatory gene signature are associated with decreased survival in diffuse infiltrating gliomas

Cody Weston, Joe Klobusicky, Jennifer Weston, James Connor, Steven A. Toms, Nicholas F. Marko

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Iron is a tightly regulated micronutrient with no physiologic means of elimination and is necessary for cell division in normal tissue. Recent evidence suggests that dysregulation of iron regulatory proteins may play a role in cancer pathophysiology. We use public data from The Cancer Genome Atlas (TCGA) to study the association between survival and expression levels of 61 genes coding for iron regulatory proteins in patients with World Health Organization Grade II-III gliomas. Using a feature selection algorithm we identified a novel, optimized subset of eight iron regulatory genes (STEAP3, HFE, TMPRSS6, SFXN1, TFRC, UROS, SLC11A2, and STEAP4) whose differential expression defines two phenotypic groups with median survival differences of 52.3 months for patients with grade II gliomas (25.9 vs. 78.2 months, p< 10 -3 ), 43.5 months for patients with grade III gliomas (43.9 vs. 87.4 months, p = 0.025), and 54.0 months when considering both grade II and III gliomas (79.9 vs. 25.9 months, p < 10 -5 ).

Original languageEnglish (US)
Article numbere0166593
JournalPloS one
Volume11
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Regulator Genes
Iron-Regulatory Proteins
regulator genes
Aberrations
Glioma
Iron
Genes
iron
Survival
regulatory proteins
Micronutrients
Set theory
neoplasms
Feature extraction
Atlases
World Health Organization
pathophysiology
dietary minerals
Cells
Health

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Weston, Cody ; Klobusicky, Joe ; Weston, Jennifer ; Connor, James ; Toms, Steven A. ; Marko, Nicholas F. / Aberrations in the iron regulatory gene signature are associated with decreased survival in diffuse infiltrating gliomas. In: PloS one. 2016 ; Vol. 11, No. 11.
@article{2630a0b88bd04eedbac4fb00881f694c,
title = "Aberrations in the iron regulatory gene signature are associated with decreased survival in diffuse infiltrating gliomas",
abstract = "Iron is a tightly regulated micronutrient with no physiologic means of elimination and is necessary for cell division in normal tissue. Recent evidence suggests that dysregulation of iron regulatory proteins may play a role in cancer pathophysiology. We use public data from The Cancer Genome Atlas (TCGA) to study the association between survival and expression levels of 61 genes coding for iron regulatory proteins in patients with World Health Organization Grade II-III gliomas. Using a feature selection algorithm we identified a novel, optimized subset of eight iron regulatory genes (STEAP3, HFE, TMPRSS6, SFXN1, TFRC, UROS, SLC11A2, and STEAP4) whose differential expression defines two phenotypic groups with median survival differences of 52.3 months for patients with grade II gliomas (25.9 vs. 78.2 months, p< 10 -3 ), 43.5 months for patients with grade III gliomas (43.9 vs. 87.4 months, p = 0.025), and 54.0 months when considering both grade II and III gliomas (79.9 vs. 25.9 months, p < 10 -5 ).",
author = "Cody Weston and Joe Klobusicky and Jennifer Weston and James Connor and Toms, {Steven A.} and Marko, {Nicholas F.}",
year = "2016",
month = "11",
day = "1",
doi = "10.1371/journal.pone.0166593",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "11",

}

Aberrations in the iron regulatory gene signature are associated with decreased survival in diffuse infiltrating gliomas. / Weston, Cody; Klobusicky, Joe; Weston, Jennifer; Connor, James; Toms, Steven A.; Marko, Nicholas F.

In: PloS one, Vol. 11, No. 11, e0166593, 01.11.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Aberrations in the iron regulatory gene signature are associated with decreased survival in diffuse infiltrating gliomas

AU - Weston, Cody

AU - Klobusicky, Joe

AU - Weston, Jennifer

AU - Connor, James

AU - Toms, Steven A.

AU - Marko, Nicholas F.

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Iron is a tightly regulated micronutrient with no physiologic means of elimination and is necessary for cell division in normal tissue. Recent evidence suggests that dysregulation of iron regulatory proteins may play a role in cancer pathophysiology. We use public data from The Cancer Genome Atlas (TCGA) to study the association between survival and expression levels of 61 genes coding for iron regulatory proteins in patients with World Health Organization Grade II-III gliomas. Using a feature selection algorithm we identified a novel, optimized subset of eight iron regulatory genes (STEAP3, HFE, TMPRSS6, SFXN1, TFRC, UROS, SLC11A2, and STEAP4) whose differential expression defines two phenotypic groups with median survival differences of 52.3 months for patients with grade II gliomas (25.9 vs. 78.2 months, p< 10 -3 ), 43.5 months for patients with grade III gliomas (43.9 vs. 87.4 months, p = 0.025), and 54.0 months when considering both grade II and III gliomas (79.9 vs. 25.9 months, p < 10 -5 ).

AB - Iron is a tightly regulated micronutrient with no physiologic means of elimination and is necessary for cell division in normal tissue. Recent evidence suggests that dysregulation of iron regulatory proteins may play a role in cancer pathophysiology. We use public data from The Cancer Genome Atlas (TCGA) to study the association between survival and expression levels of 61 genes coding for iron regulatory proteins in patients with World Health Organization Grade II-III gliomas. Using a feature selection algorithm we identified a novel, optimized subset of eight iron regulatory genes (STEAP3, HFE, TMPRSS6, SFXN1, TFRC, UROS, SLC11A2, and STEAP4) whose differential expression defines two phenotypic groups with median survival differences of 52.3 months for patients with grade II gliomas (25.9 vs. 78.2 months, p< 10 -3 ), 43.5 months for patients with grade III gliomas (43.9 vs. 87.4 months, p = 0.025), and 54.0 months when considering both grade II and III gliomas (79.9 vs. 25.9 months, p < 10 -5 ).

UR - http://www.scopus.com/inward/record.url?scp=85002723477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002723477&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0166593

DO - 10.1371/journal.pone.0166593

M3 - Article

C2 - 27898674

AN - SCOPUS:85002723477

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 11

M1 - e0166593

ER -